The Pediatric Vaccine Industry Is Likely To See Accelerated Growth As It Moves Toward 2030

 The Business Research Company’s 2026 market reports incorporate enhanced features, including market attractiveness scoring and analysis, total addressable market evaluation, a company scoring matrix, an interactive Excel data dashboard, refined supply chain analysis, insights on emerging startups, and overviews of key products, all aimed at improving the depth, usability, and strategic relevance of the insights delivered.

 
 What Will Be The Estimated Market Value Of The Pediatric Vaccine Market By The End Of The Forecast Timeline?
 The pediatric vaccine market size has grown rapidly in recent years. It will grow from $57.51 billion in 2025 to $65.01 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to rising prevalence of preventable childhood diseases, government-led immunization campaigns, advancements in vaccine adjuvants, growing awareness of pediatric health, expansion of cold chain infrastructure.
 
 The pediatric vaccine market size is expected to see rapid growth in the next few years. It will grow to $107.8 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to innovations in mRNA and DNA vaccines, increasing investment in pediatric vaccine R&D, digital health monitoring integration, expansion of emerging market healthcare infrastructure, partnerships between biotech firms and global health organizations. Major trends in the forecast period include increased focus on vaccine accessibility in low-income regions, rising adoption of combination vaccines, expansion of immunization programs in schools, development of novel pediatric vaccines for rare diseases, growing public-private partnerships in vaccine research.
 
 Download Your Free Report Sample:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=2824&type=smp
 
 Which Drivers Are Expected To Sustain Growth In The Pediatric Vaccine Market? 
 The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the pediatric vaccine market.
 
 
 
 Who Are The Leading Participants In The Pediatric Vaccine Market?
 The pediatric vaccine market covered in this report is segmented — 
 
 1) By Vaccine Type: Monovalent, Multivalent 
 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies
 3) By Application: Infectious Disease, Allergy, Cancer
 
 Subsegments:
 1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines 
 2) By Multivalent: Combination Vaccines, Polyvalent Vaccines
 
 What Are The Most Important Trends In The Pediatric Vaccine Market?
 Major companies operating in the pediatric vaccine market are focusing on product approvals to better meet the needs of their existing consumers. ABRYSVO is a vaccine authorized by the FDA for use in pregnant women for the prevention of lower respiratory tract disease (LRTD) and severe LRTD triggered by respiratory syncytial virus (RSV) in children till 6 months of age. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company announced the U.S. FDA approval of Pfizer’s ABRYSVO vaccine for the Avoidance of Respiratory Syncytial Virus (RSV) in Infants by active immunization of pregnant women 32–36 weeks gestational age. The first and only maternal vaccination approved in the United States to help prevent newborns against lower respiratory tract illness (LRTD) and severe LRTD caused by RSV from birth to six months of age. 
 
 How Is The Pediatric Vaccine Market Divided Into Segment Categories?
 The pediatric vaccine market covered in this report is segmented — 
 
 1) By Vaccine Type: Monovalent, Multivalent 
 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies
 3) By Application: Infectious Disease, Allergy, Cancer
 
 Subsegments:
 1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines 
 2) By Multivalent: Combination Vaccines, Polyvalent Vaccines
 
 Explore the Complete Pediatric Vaccine Market Report:
 https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
 
 Which Regions Present The Greatest Opportunities For Expansion In The Pediatric Vaccine Market?
 https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
 
 #Contact Us:#
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: marketing@tbrc.info
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company